CN113797215B - Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof - Google Patents
Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof Download PDFInfo
- Publication number
- CN113797215B CN113797215B CN202111013751.3A CN202111013751A CN113797215B CN 113797215 B CN113797215 B CN 113797215B CN 202111013751 A CN202111013751 A CN 202111013751A CN 113797215 B CN113797215 B CN 113797215B
- Authority
- CN
- China
- Prior art keywords
- parts
- glycoside
- composition containing
- solution
- pinoresinol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 90
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 title claims abstract description 48
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 235000007221 pinoresinol Nutrition 0.000 title claims abstract description 48
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- KCIQZCNOUZCRGH-VOBQZIQPSA-N Cycloolivil Chemical compound C1([C@@H]2[C@@H](CO)[C@](O)(CO)CC=3C=C(C(=CC=32)O)OC)=CC=C(O)C(OC)=C1 KCIQZCNOUZCRGH-VOBQZIQPSA-N 0.000 title claims abstract description 24
- KCIQZCNOUZCRGH-UHFFFAOYSA-N cycloolivil Natural products C1=2C=C(O)C(OC)=CC=2CC(O)(CO)C(CO)C1C1=CC=C(O)C(OC)=C1 KCIQZCNOUZCRGH-UHFFFAOYSA-N 0.000 title claims abstract description 24
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 58
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 31
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 31
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229960001285 quercetin Drugs 0.000 claims abstract description 31
- 235000005875 quercetin Nutrition 0.000 claims abstract description 31
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 30
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 30
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 30
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 30
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 30
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 30
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 30
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 22
- 241000208689 Eucommia ulmoides Species 0.000 claims abstract 5
- 241001122767 Theaceae Species 0.000 claims description 67
- 239000000243 solution Substances 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 43
- 229930182490 saponin Natural products 0.000 claims description 43
- 150000007949 saponins Chemical class 0.000 claims description 43
- 239000012153 distilled water Substances 0.000 claims description 38
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 239000011347 resin Substances 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 14
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 12
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 11
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 10
- 229940083466 soybean lecithin Drugs 0.000 claims description 10
- BVHIKUCXNBQDEM-JSNMRZPZSA-N (3s,4r,5s)-5-(4-hydroxy-3-methoxyphenyl)-3-[(4-hydroxy-3-methoxyphenyl)methyl]-4-(hydroxymethyl)oxolan-3-ol Chemical compound C1=C(O)C(OC)=CC(C[C@]2(O)[C@@H]([C@H](OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 BVHIKUCXNBQDEM-JSNMRZPZSA-N 0.000 claims description 9
- NYDZRKZVFLLTLO-UHFFFAOYSA-N Neoolivil Natural products C1=C(O)C(OC)=CC(C2C(C(CO)C(O2)C=2C=C(OC)C(O)=CC=2)CO)=C1 NYDZRKZVFLLTLO-UHFFFAOYSA-N 0.000 claims description 9
- BVHIKUCXNBQDEM-UHFFFAOYSA-N Olivil Natural products C1=C(O)C(OC)=CC(CC2(O)C(C(OC2)C=2C=C(OC)C(O)=CC=2)CO)=C1 BVHIKUCXNBQDEM-UHFFFAOYSA-N 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000003463 adsorbent Substances 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 208000003947 Knee Osteoarthritis Diseases 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 claims description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 206010003246 arthritis Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 9
- 244000237330 gutta percha tree Species 0.000 description 30
- 241000700159 Rattus Species 0.000 description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- 238000010828 elution Methods 0.000 description 10
- 206010042674 Swelling Diseases 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 239000012535 impurity Substances 0.000 description 7
- 210000000629 knee joint Anatomy 0.000 description 7
- 239000003480 eluent Substances 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940100601 interleukin-6 Drugs 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 241000213006 Angelica dahurica Species 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 241000195954 Lycopodium clavatum Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 240000002245 Acer pensylvanicum Species 0.000 description 1
- 235000006760 Acer pensylvanicum Nutrition 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 235000017965 Asarum canadense Nutrition 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000218158 Clematis Species 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 235000000385 Costus speciosus Nutrition 0.000 description 1
- 244000241463 Cullen corylifolium Species 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 241000241550 Cyathula Species 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 241000123589 Dipsacus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 235000015912 Impatiens biflora Nutrition 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 206010072970 Meniscus injury Diseases 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 244000131360 Morinda citrifolia Species 0.000 description 1
- 235000008898 Morinda citrifolia Nutrition 0.000 description 1
- 235000008248 Morinda citrifolia var citrifolia Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 241001404789 Smilax glabra Species 0.000 description 1
- 241000913745 Spatholobus Species 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 235000005155 Tanacetum balsamita Nutrition 0.000 description 1
- 241000606265 Valeriana jatamansi Species 0.000 description 1
- 241001227561 Valgus Species 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 235000014687 Zingiber zerumbet Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 244000195896 dadap Species 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000017524 noni Nutrition 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 208000005528 popliteal cyst Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to a composition containing pinoresinol and cyclopolybdenum-9-glycoside, and a preparation method and application thereof. The composition comprises the following components: cycloolivil 9-glycoside, chlorogenic acid, pinoresinol, eucommia ulmoides alcohol, and quercetin. The composition can effectively improve the effect of the composition on treating knee arthritis, and meanwhile, the utilization rate of the medicine is higher, so that the cost is effectively reduced, and meanwhile, the side effect of the medicine is reduced.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a composition containing pinoresinol and cyclopolybdenum-9-glycoside, and a preparation method and application thereof.
Background
Knee arthritis is a disorder based on degenerative pathological changes. The symptoms of the traditional Chinese medicine are red and sore knees, stair pain, and discomfort of knee pain when sitting and standing. Patients also show swelling, bouncing, hydrops and the like, and if the patients are not treated in time, joint deformity and disability can be caused. Joint diseases such as gonarthromeningitis, ligament injury, meniscus injury, knee joint dissociative body, popliteal cyst, patellar softening, goose foot bursitis, gonvarus/valgus and the like are also frequently caused at knee joint parts. The traditional medicines for treating knee osteoarthritis are various, for example, chinese patent application CN201910540161.2 provides a traditional Chinese medicine preparation for treating knee osteoarthritis, which comprises the following traditional Chinese medicine raw materials in parts by weight: 15-20 parts of eucommia ulmoides, 15-20 parts of epimedium herb, 5-10 parts of teasel root, 20-30 parts of medicinal cyathula root, 5-10 parts of malaytea scurfpea fruit, 15-20 parts of notopterygium root, 5-10 parts of bighead atractylodes rhizome, 15-20 parts of acanthopanax root, 10-20 parts of Chinese angelica, 2-5 parts of platycladi seed, 5-10 parts of cassia bark, 5-10 parts of lycopodium clavatum, 15-20 parts of curcuma zedoary, 5-10 parts of medlar, 5-10 parts of notopterygium root, 2-5 parts of liquorice, 5-10 parts of rhizoma atractylodis, 1-2 parts of wrinkled gianthyssop herb, 5-10 parts of root of red-rooted salvia, 10-20 parts of oyster, 10-20 parts of radix angelicae pubescentis, 2-5 parts of coix seed, 5-10 parts of papaya and 2-5 parts of smilax glabra. The preparation can effectively relieve pain of patients and can simultaneously increase bone density.
Chinese patent application CN201610170627.0 discloses a traditional Chinese medicine composition for treating knee arthritis, wherein the formula of the traditional Chinese medicine composition for treating knee arthritis is as follows: 12-18 parts of raw radix aconiti, 12-18 parts of raw kusnezoff monkshood root, 12-18 parts of manchurian wildginger, 12-18 parts of peach kernel, 12-18 parts of twotooth achyranthes root, 16-24 parts of incised notopterygium rhizome, 22-28 parts of common clubmoss herb, 22-28 parts of medicinal indianmulberry root, 22-28 parts of clematis root, 22-28 parts of garden balsam stem, 22-28 parts of rhubarb, 22-28 parts of szechuan lovage rhizome, 20-30 parts of Chinese angelica, 20-30 parts of suberect spatholobus stem, 20-30 parts of erythrina bark and 20-30 parts of mulberry twig. Has effects in dispelling pathogenic wind, removing dampness, promoting blood circulation, activating blood circulation, dredging meridian passage, relieving pain, promoting blood circulation, and relieving pain.
Most of the medicaments in the prior art are rich in raw materials, have a certain effect of relieving the knee arthritis, but do not effectively improve the utilization efficiency of the medicaments, the curative effect still needs to be improved, meanwhile, the interaction among the raw materials is ambiguous, and the side effect is great in the use process of patients.
The invention aims to provide a composition for treating knee arthritis, which can effectively improve the effect of the composition on treating knee arthritis, has higher utilization rate of medicines, and reduces side effects of the medicines while effectively reducing the cost.
Disclosure of Invention
In order to overcome the technical problems, the invention provides a composition containing pinoresinol and cyclopolybdarietin 9-glycoside, and a preparation method and application thereof. The composition has good effect of treating knee arthritis, and simultaneously, the utilization rate of the medicine is high, so that the cost is effectively reduced, and the side effect of the medicine is reduced.
In order to achieve the above object, the technical scheme provided by the invention is as follows:
a composition comprising a cyclic olivil 9-glycoside, comprising the following components: cycloolivil 9-glycoside, chlorogenic acid, pinoresinol, eucommia ulmoides alcohol, and quercetin.
Preferably, the composition containing the cyclopolyartarin 9-glycoside comprises the following components in parts by weight: 5-20 parts of cyclopolybdarietin 9-glucoside, 1-10 parts of chlorogenic acid, 5-15 parts of pinoresinol, 1-5 parts of eucommia ulmoides alcohol and 1-5 parts of quercetin.
Preferably, the composition containing the cyclopolyartarin 9-glycoside comprises the following components in parts by weight: 8-12 parts of cycloolivil 9-glucoside, 5-7 parts of chlorogenic acid, 7-11 parts of pinoresinol, 2-4 parts of eucommia ulmoides alcohol and 2-3 parts of quercetin.
Another object of the present invention is to provide a method for preparing the composition containing the cyclic olivil 9-glycoside, comprising the steps of:
(1) Adding a surfactant A into distilled water, heating, sequentially dissolving the 9-glucoside of the cycloolivil, chlorogenic acid and pinoresinol into the distilled water, and stirring to form a solution 1;
(2) Adding a surfactant B into distilled water, and then adding eucommia ulmoides alcohol and quercetin to form a solution 2;
(3) Mixing the solution 1 and the solution 2, and stirring to obtain the composition containing pinoresinol and the 9-glucoside of the cycloolivil.
Preferably, in step (1), the surfactant a is any one or more of soybean lecithin, octyl- β -D-glucopyranoside, dodecyl- β -D-maltopyranoside, and N-dodecyl-N-methyl glucamide.
Preferably, in the step (1), the surfactant A is a mixture of N-dodecyl-N-methyl glucamide and soybean lecithin in a mass ratio of 4-6:1.
Preferably, the addition amount of the surfactant A is 0.1-0.5% of the mass of distilled water.
Preferably, the distilled water is added in an amount of 2-3 times the total mass of the 9-glycoside of the olivil, chlorogenic acid and pinoresinol.
Preferably, in step (1), the heating temperature is 30-45 ℃.
Preferably, the surfactant B is tea saponin, and the addition amount of the tea saponin is 0.1-1% of the total mass of the eucommia ulmoides alcohol and the quercetin.
Preferably, the preparation method of the tea saponin comprises the following steps:
pulverizing tea seed cake, soaking in hot water for extraction, filtering, treating the extractive solution with macroporous adsorbent resin, eluting with ethanol water solution, and drying to obtain tea saponin.
Preferably, the temperature of the hot water is 60-80 ℃, and the extraction time is 3-4h.
Preferably, sodium carbonate is added in the extraction process, wherein the addition amount of the sodium carbonate is 5-10% of the mass of the tea seed cake.
Preferably, the macroporous adsorption resin is D3520 or D4006 macroporous adsorption resin.
The specific process of eluting the ethanol water solution comprises eluting with 80-95% ethanol water solution to remove impurities, eluting with 30-45% ethanol, and collecting eluate.
Preferably, the elution rate of 80-95% by volume fraction is 1-3BV/h, and the amount is 1-2BV.
Preferably, the elution rate of 30-45% by volume is 1-3BV/h and the amount is 3-5BV.
The invention also aims to provide the application of the composition containing pinoresinol and the cyclophilin 9-glycoside in preparing the knee osteoarthritis medicine.
Another object of the present invention is to provide a formulation of the composition containing pinoresinol and cyclopolytin 9-glycoside, which is a granule, a tablet, a capsule or an oral liquid.
Compared with the prior art, the invention has the technical advantages that:
(1) The composition containing the pinoresinol and the 9-glucoside of the cyclopolyol has better effect of treating knee osteoarthritis and has better synergistic effect with chlorogenic acid, pinoresinol, eucommia ulmoides alcohol and quercetin.
(2) The surfactant is added in the process of preparing the composition, so that the storage stability of the composition can be improved, and the drug effect stability can be improved.
(3) According to the invention, the tea saponin is added in the preparation process, so that on one hand, the stability of the composition can be effectively promoted, and on the other hand, the tea saponin can also cooperate with eucommia ulmoides alcohol and quercetin to promote the drug effect of the composition.
Detailed Description
The present invention will be described by way of specific examples, to facilitate understanding and grasping of the technical solution of the present invention, but the present invention is not limited thereto. The experimental methods described in the following examples are all conventional methods unless otherwise specified; the reagents and materials, unless otherwise specified, are commercially available.
Example 1
The composition containing the cyclopolyartarin 9-glycoside comprises the following components in parts by weight: 12 parts of cyclopolybdarietin 9-glucoside, 7 parts of chlorogenic acid, 7 parts of pinoresinol, 4 parts of eucommia ulmoides alcohol and 2 parts of quercetin.
The preparation method of the composition containing the cyclopolyartrin 9-glycoside comprises the following steps:
(1) Taking distilled water which is 2 times of the total mass of the cyclopolyartrin 9-glucoside, the chlorogenic acid and the pinoresinol, and adding 0.3 weight percent of distilled water into the distilled water, wherein the mass ratio is 5:1, heating the mixture of N-dodecyl-N-methyl glucamide and soybean lecithin to 40 ℃, sequentially dissolving the 9-glucoside of the cycloolivil, chlorogenic acid and pinoresinol into the mixture, and stirring the mixture to form a solution 1;
(2) Adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.3wt% of the total mass of the eucommia ulmoides alcohol and the quercetin, and adding the eucommia ulmoides alcohol and the quercetin to form a solution 2;
(3) Mixing the solution 1 and the solution 2, and stirring to obtain the composition containing pinoresinol and the 9-glucoside of the cycloolivil.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 70 ℃, adding sodium carbonate accounting for 6wt% of the mass of the tea seed cakes, soaking and extracting for 3 hours, filtering, treating an extracting solution by using D3520 macroporous absorbent resin, eluting by using an ethanol water solution with the volume fraction of 80% of 2BV to remove impurities, wherein the eluting rate is 2BV/h; eluting with ethanol with volume fraction of 35% of 4BV, and collecting eluate with elution rate of 2BV/h; and drying the eluent to obtain the tea saponin.
Example 2
The composition containing the cyclopolyartarin 9-glycoside comprises the following components in parts by weight: 5 parts of cyclopolybdarietin 9-glucoside, 5 parts of chlorogenic acid, 11 parts of pinoresinol, 2 parts of eucommia ulmoides alcohol and 1 part of quercetin.
The preparation method of the composition containing the cyclopolyartrin 9-glycoside comprises the following steps:
(1) Taking distilled water which is 3 times of the total mass of the cyclopolyartrin 9-glucoside, the chlorogenic acid and the pinoresinol, adding 0.5 weight percent of a mixture of N-dodecyl-N-methyl glucamide and soybean lecithin with the mass ratio of 4:1 into the distilled water, heating to 30 ℃, sequentially dissolving the cyclopolyartrin 9-glucoside, the chlorogenic acid and the pinoresinol into the distilled water, and stirring to form a solution 1;
(2) Adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.1% of the total mass of the eucommia ulmoides alcohol and the quercetin, and adding the eucommia ulmoides alcohol and the quercetin to form a solution 2;
(3) Mixing the solution 1 and the solution 2, and stirring to obtain the composition containing pinoresinol and the 9-glucoside of the cycloolivil.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 60 ℃, adding sodium carbonate accounting for 5wt% of the mass of the tea seed cakes, soaking and extracting for 3 hours, filtering, treating an extracting solution by using D4006 macroporous adsorbent resin, eluting by using 1BV of ethanol water solution with the volume fraction of 95% to remove impurities, wherein the eluting rate is 1BV/h; eluting with 45% ethanol of 5BV at an elution rate of 1BV/h; and drying the eluent to obtain the tea saponin.
Example 3
The composition containing the cyclopolyartarin 9-glycoside comprises the following components in parts by weight: 20 parts of cyclopolybdarietin 9-glucoside, 10 parts of chlorogenic acid, 11 parts of pinoresinol, 5 parts of eucommia ulmoides alcohol and 5 parts of quercetin.
The preparation method of the composition containing the cyclopolyartrin 9-glycoside comprises the following steps:
(1) Taking distilled water which is 2-3 times of the total mass of the cyclopolybdarietin 9-glucoside, the chlorogenic acid and the pinoresinol, adding 0.1 weight percent of a mixture of N-dodecyl-N-methyl glucamide and soybean lecithin with the mass ratio of 6:1 into the distilled water, heating to 45 ℃, sequentially dissolving the cyclopolybdarietin 9-glucoside, the chlorogenic acid and the pinoresinol into the distilled water, and stirring to form a solution 1;
(2) Adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 1% of the total mass of the eucommia ulmoides alcohol and the quercetin, and then adding the eucommia ulmoides alcohol and the quercetin to form a solution 2;
(3) Mixing the solution 1 and the solution 2, and stirring to obtain the composition containing pinoresinol and the 9-glucoside of the cycloolivil.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 80 ℃, adding sodium carbonate accounting for 10wt% of the mass of the tea seed cakes, soaking and extracting for 4 hours, filtering, treating an extracting solution by using D4006 macroporous adsorbent resin, eluting by using ethanol water solution with the volume fraction of 80% of 2BV to remove impurities, wherein the eluting rate is 3BV/h; eluting with ethanol with volume fraction of 3BV of 30%, and collecting eluate with elution rate of 3BV/h; and drying the eluent to obtain the tea saponin.
Example 4
The composition containing the cyclopolyartarin 9-glycoside comprises the following components in parts by weight: 12 parts of cyclopolybdarietin 9-glucoside, 7 parts of chlorogenic acid, 7 parts of pinoresinol, 4 parts of eucommia ulmoides alcohol and 2 parts of quercetin.
The preparation method of the composition containing the cyclopolyartrin 9-glycoside comprises the following steps:
(1) Taking distilled water which is 2 times of the total mass of the 9-glucoside of the cycloolivil, the chlorogenic acid and the pinoresinol, adding 0.3 weight percent of soybean lecithin into the distilled water, heating to 40 ℃, sequentially dissolving the 9-glucoside of the cycloolivil, the chlorogenic acid and the pinoresinol into the distilled water, and stirring to form a solution 1;
(2) Adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.3wt% of the total mass of the eucommia ulmoides alcohol and the quercetin, and adding the eucommia ulmoides alcohol and the quercetin to form a solution 2;
(3) Mixing the solution 1 and the solution 2, and stirring to obtain the composition containing pinoresinol and the 9-glucoside of the cycloolivil.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 70 ℃, adding sodium carbonate accounting for 6wt% of the mass of the tea seed cakes, soaking and extracting for 3 hours, filtering, treating an extracting solution by using D3520 macroporous absorbent resin, eluting by using an ethanol water solution with the volume fraction of 80% of 2BV to remove impurities, wherein the eluting rate is 2BV/h; eluting with ethanol with volume fraction of 35% of 4BV, and collecting eluate with elution rate of 2BV/h; and drying the eluent to obtain the tea saponin.
Example 5
The composition containing the cyclopolyartarin 9-glycoside comprises the following components in parts by weight: 12 parts of cyclopolybdarietin 9-glucoside, 7 parts of chlorogenic acid, 7 parts of pinoresinol, 4 parts of eucommia ulmoides alcohol and 2 parts of quercetin.
The preparation method of the composition containing the cyclopolyartrin 9-glycoside comprises the following steps:
(1) Taking distilled water which is 2 times of the total mass of the 9-glucoside of the cycloolivil, the chlorogenic acid and the pinoresinol, adding 0.3 weight percent of dodecyl-beta-D-maltopyranoside into the distilled water, heating to 40 ℃, sequentially dissolving the 9-glucoside of the cycloolivil, the chlorogenic acid and the pinoresinol into the distilled water, and stirring to form a solution 1;
(2) Adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.3wt% of the total mass of the eucommia ulmoides alcohol and the quercetin, and adding the eucommia ulmoides alcohol and the quercetin to form a solution 2;
(3) Mixing the solution 1 and the solution 2, and stirring to obtain the composition containing pinoresinol and the 9-glucoside of the cycloolivil.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 70 ℃, adding sodium carbonate accounting for 6wt% of the mass of the tea seed cakes, soaking and extracting for 3 hours, filtering, treating an extracting solution by using D3520 macroporous absorbent resin, eluting by using an ethanol water solution with the volume fraction of 80% of 2BV to remove impurities, wherein the eluting rate is 2BV/h; eluting with ethanol with volume fraction of 35% of 4BV, and collecting eluate with elution rate of 2BV/h; and drying the eluent to obtain the tea saponin.
Comparative example 1
The difference compared to example 1 is that eucommia ulmoides alcohol is used instead of quercetin.
The composition containing the cyclopolyartarin 9-glycoside comprises the following components in parts by weight: 12 parts of cyclopolybdarietin 9-glucoside, 7 parts of chlorogenic acid, 7 parts of pinoresinol and 6 parts of eucommia ulmoides alcohol.
The preparation method of the composition containing the cyclopolyartrin 9-glycoside comprises the following steps:
(1) Taking distilled water which is 2 times of the total mass of the cyclopolyartrin 9-glucoside, the chlorogenic acid and the pinoresinol, and adding 0.3 weight percent of distilled water into the distilled water, wherein the mass ratio is 5:1, heating the mixture of N-dodecyl-N-methyl glucamide and soybean lecithin to 40 ℃, sequentially dissolving the 9-glucoside of the cycloolivil, chlorogenic acid and pinoresinol into the mixture, and stirring the mixture to form a solution 1;
(2) Adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.3wt% of the total mass of eucommia ulmoides alcohol, and adding the eucommia ulmoides alcohol to form a solution 2;
(3) Mixing the solution 1 and the solution 2, and stirring to obtain the composition containing pinoresinol and the 9-glucoside of the cycloolivil.
The preparation method of the tea saponin is the same as that of the example 1.
Comparative example 2
The difference compared to example 1 is that citric acid is used instead of chlorogenic acid.
The composition containing the cyclopolyartarin 9-glycoside comprises the following components in parts by weight: 12 parts of cyclopolybdarietin 9-glucoside, 7 parts of citric acid, 7 parts of pinoresinol, 4 parts of eucommia ulmoides alcohol and 2 parts of quercetin.
The preparation method of the composition containing the cyclopolyartrin 9-glycoside comprises the following steps:
(1) Taking distilled water which is 2 times of the total mass of the cyclopolyartrin 9-glucoside, the citric acid and the pinoresinol, and adding 0.3 weight percent of distilled water into the distilled water, wherein the mass ratio is 5:1, heating the mixture of N-dodecyl-N-methyl glucamide and soybean lecithin to 40 ℃, sequentially dissolving the 9-glucoside of the cycloolivil, the citric acid and the pinoresinol into the mixture, and stirring the mixture to form a solution 1;
(2) Adding tea saponin into distilled water, wherein the adding amount of the tea saponin is 0.3wt% of the total mass of the eucommia ulmoides alcohol and the quercetin, and adding the eucommia ulmoides alcohol and the quercetin to form a solution 2;
(3) Mixing the solution 1 and the solution 2, and stirring to obtain the composition containing pinoresinol and the 9-glucoside of the cycloolivil.
The preparation method of the tea saponin comprises the following steps: crushing tea seed cakes, adding the crushed tea seed cakes into hot water at 70 ℃, adding sodium carbonate accounting for 6wt% of the mass of the tea seed cakes, soaking and extracting for 3 hours, filtering, treating an extracting solution by using D3520 macroporous absorbent resin, eluting by using an ethanol water solution with the volume fraction of 80% of 2BV to remove impurities, wherein the eluting rate is 2BV/h; eluting with ethanol with volume fraction of 35% of 4BV, and collecting eluate with elution rate of 2BV/h; and drying the eluent to obtain the tea saponin.
Comparative example 3
The difference compared with example 1 is that the preparation method of tea saponin is different.
A composition containing 9-glycoside of Cycloolivil comprises the same components as in example 1.
The preparation method of the composition containing the cyclopolyartrin 9-glycoside comprises the following steps:
(1) - (3) the same as in example 1.
The preparation method of the tea saponin comprises the following steps:
pulverizing tea seed cake, soaking in 70deg.C hot water for 3 hr, filtering, treating the extractive solution with D3520 macroporous adsorbent resin, eluting with 2BV 90% ethanol water solution at an elution rate of 2 BV/hr, eluting with 4BV 40% ethanol at an elution rate of 2 BV/hr, eluting, collecting eluate, and drying to obtain tea saponin.
1. Experimental experiment of anti-inflammatory action of auricle swelling of rat caused by xylene
SPF-class healthy male Wistar rats were divided into 10 groups of 200+ -20 g, each group of 6 animals, which were blank group, positive drug group, examples 1-5 group, and comparative examples 1-3 group, respectively. The right ear of each rat was coated with xylene, 50 ul/mouse, and 30min later administered in the following groups: the blank group was not given any drug; examples 1-5 and comparative examples 1-3 were given the compositions prepared in the respective groups at an effective level of 0.5mg/kg, respectively, and after application to the right ears of rats, the compositions were massaged appropriately to promote drug absorption; the positive drug group uses commercial loxoprofen sodium gel paste (Hunan Jiudian pharmacy), and the right ear of the rat is coated on both sides to be properly massaged to promote drug absorption. After 1h, animals were sacrificed from cervical dislocation, round lugs were respectively punched on the same parts of the two ears by a 6mm diameter puncher, the mass was weighed by a precision torsion balance, and the swelling degree and swelling rate were calculated, and the results are shown in Table 1.
Table 1 swelling degree and swelling Rate data
In the same list, different symbols have significant differences, and P is less than 0.05.
As can be seen from Table 1, the compositions provided in the examples 1-5 and comparative examples 1-3 reduced the swelling of the auricles of rats due to xylene, which demonstrates that the compositions provided by the present invention have a better anti-inflammatory effect, as compared to the blank. Meanwhile, the raw material composition and the preparation method of the composition have great influence on the effect.
2. Model experiment of knee osteoarthritis in rats
60 SD rats were selected, and the weight of the rats was 200.+ -.20 g, and the rats were randomly divided into 10 groups of 6 rats each, which were respectively a normal group, a model group, examples 1-5 groups, and comparative examples-3 groups.
Except for normal groups, rats were injected with papain into the joint cavity to replicate KOA model; the rats were treated with skin preparation and disinfection, the right forelimb knee joint parts and the hairs below were shaved off, and after skin disinfection with 75% ethanol, the right forelimb knee joint cavity was injected with 0.2mL of 4% papain solution once every 2d for 2 weeks. After 14d, the following symptoms were found in the rats, indicating successful replication: redness, swelling, fever and pain of the knee joint on the right front side, with swelling of soft tissues or hydrops; stiffness and limited mobility in the right anterior knee joint and surrounding; the pathological examination result of the knee joint at the right front side shows that a large amount of exudates appear in the joint cavity; the cartilage surface is not smooth, and there are arthritis pathological changes such as synovial hyperplasia or adhesion. On day 2 after successful molding, rats of each of the groups 1 to 5 and comparative examples 1 to 3 were subjected to respective groups of prepared compositions except for the normal group and the model group which were subjected to gastric lavage with physiological saline, and the rats of each group were subjected to gastric lavage at a dose of 10mg/kg/d for intervention, and femoral arterial blood was collected from each group of rats after 4 weeks of intervention at 1500 rpm.min -1 Centrifuging for 10min, collecting serum, and detecting IL-6 (interleukin-6), TNF-alpha (tumor necrosis factor-alpha), and IL-1β (interleukin-1β) levels by enzyme-linked immunosorbent assay (enzyme-linked immunosorbent assay kit manufacturer: wohman Irett biosciences). The results are shown in Table 2.
TABLE 2 inflammatory factor levels
| Test group | IL-6(ng·L -1 ) | TNF-α(ng·L -1 ) | IL-1β(ng·L -1 ) |
| Blank group | 18.32±2.37 a | 22.15±6.14 f | 6.01±1.09* |
| Model group | 44.26±4.51 b | 41.34±4.11 g | 12.65±2.34 # |
| Example 1 | 23.57±5.34 c | 25.43±3.57 h | 7.46±0.87 △ |
| Example 2 | 24.61±3.08 c | 25.69±8.21 h | 7.29±1.54 △ |
| Example 3 | 23.68±1.55 c | 26.07±6.47 h | 7.54±2.05 △ |
| Example 4 | 30.25±2.67 d | 28.34±5.22 h | 8.02±3.11 ▼ |
| Example 5 | 31.08±3.26 d | 29.10±4.28 h | 8.71±2.62 ▼ |
| Comparative example 1 | 34.53±6.64 e | 33.76±9.14 i | 10.89±1.03 ◇ |
| Comparative example 2 | 37.28±4.09 e | 36.21±5.67 i | 11.32±5.43 ◇ |
| Comparative example 3 | 33.56±5.12 e | 31.43±4.39 i | 9.86±2.19 ◇ |
In the same list, different letters or symbols have significant differences, and P is less than 0.05.
As can be seen from Table 2, the compositions provided in the examples 1-5 and comparative examples 1-3 effectively interfere with serum inflammatory factor levels, compared to the blank, demonstrating that the compositions provided in the present invention have better effect in treating knee osteoarthritis. Meanwhile, the raw material composition and the preparation method of the composition have great influence on the effect.
The foregoing detailed description is directed to one of the possible embodiments of the present invention, which is not intended to limit the scope of the invention, but is to be accorded the full scope of all such equivalents and modifications so as not to depart from the scope of the invention.
Claims (12)
1. The composition containing the cyclopolyartarin 9-glycoside is characterized by comprising the following active ingredients in parts by weight: 5-20 parts of cyclopolybdarietin 9-glucoside, 1-10 parts of chlorogenic acid, 5-15 parts of pinoresinol, 1-5 parts of eucommia ulmoides alcohol and 1-5 parts of quercetin; the composition containing the cyclopolyartrin 9-glycoside also needs to be added with a surfactant in the preparation process, wherein the surfactant comprises tea saponin, and the preparation method of the tea saponin comprises the following steps: pulverizing tea seed cake, soaking in hot water, extracting, adding sodium carbonate, filtering, treating the extractive solution with macroporous adsorbent resin, eluting with ethanol water solution, and drying to obtain tea saponin.
2. The composition containing the cyclopolyolivil 9-glycoside according to claim 1, wherein the active ingredient consists of the following components in parts by weight: 8-12 parts of cycloolivil 9-glucoside, 5-7 parts of chlorogenic acid, 7-11 parts of pinoresinol, 2-4 parts of eucommia ulmoides alcohol and 2-3 parts of quercetin.
3. Process for the preparation of a composition comprising a cyclic olivil 9-glycoside according to any one of claims 1 to 2, characterized in that it comprises the following steps:
(1) Adding a surfactant A into distilled water, heating, sequentially dissolving the 9-glucoside of the cycloolivil, chlorogenic acid and pinoresinol into the distilled water, and stirring to form a solution 1;
(2) Adding a surfactant B into distilled water, and then adding eucommia ulmoides alcohol and quercetin to form a solution 2;
(3) Mixing the solution 1 and the solution 2, and stirring.
4. A process for the preparation of a composition comprising a cyclic olivil 9-glycoside according to claim 3, wherein in step (1), the surfactant a is any one or more of soybean lecithin, octyl- β -D-glucopyranoside, dodecyl- β -D-maltopyranoside and N-dodecyl-N-methyl glucamide; the addition amount of the surfactant A is 0.1-0.5% of the mass of distilled water; the addition amount of the distilled water is 2-3 times of the total mass of the 9-glucoside of the cyclopolybdarietin, the chlorogenic acid and the pinoresinol.
5. The method for preparing a composition containing cyclopolyolivil 9-glycoside according to claim 4, wherein in the step (1), the surfactant A is a mixture of N-dodecyl-N-methyl glucamide and soybean lecithin in a mass ratio of 4-6:1.
6. The method for preparing the composition containing the cyclopolyartarin 9-glycoside according to claim 3, wherein the surfactant B is tea saponin, and the addition amount of the tea saponin is 0.1-1% of the total mass of the eucommia ulmoides alcohol and the quercetin.
7. The method for preparing the composition containing the cyclopolybdenum-phenyl-amine 9-glycoside according to claim 6, wherein the method for preparing the tea saponin comprises the following steps: pulverizing tea seed cake, soaking in hot water for extraction, filtering, treating the extractive solution with macroporous adsorbent resin, eluting with ethanol water solution, and drying to obtain tea saponin.
8. The method for preparing a composition containing cyclopolyartocarpin 9-glycoside according to claim 7, wherein sodium carbonate is added during the extraction process, and the addition amount of sodium carbonate is 5-10% of the mass of the tea seed cake.
9. The method for preparing a composition containing cyclopolyolivil 9-glycoside according to claim 7, wherein the macroporous adsorbent resin is D3520 or D4006 type macroporous adsorbent resin.
10. The method for preparing the composition containing the cyclopolyolivil 9-glycoside according to claim 7, wherein the ethanol aqueous solution is eluted by eluting with 80-95% ethanol aqueous solution by volume fraction, eluting with 30-45% ethanol, and collecting the eluate.
11. Use of a composition comprising a cyclic olivil 9-glycoside according to any one of claims 1-2 or a composition comprising a cyclic olivil 9-glycoside prepared by the method of any one of claims 3-10 for the preparation of a medicament for treating knee osteoarthritis.
12. A formulation of a composition comprising a cyclic olivil 9-glycoside according to any one of claims 1-2 or a composition comprising a cyclic olivil 9-glycoside prepared by the method of any one of claims 3-10, wherein the formulation is a granule, tablet, capsule or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111013751.3A CN113797215B (en) | 2021-08-31 | 2021-08-31 | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111013751.3A CN113797215B (en) | 2021-08-31 | 2021-08-31 | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113797215A CN113797215A (en) | 2021-12-17 |
| CN113797215B true CN113797215B (en) | 2023-11-24 |
Family
ID=78894484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111013751.3A Active CN113797215B (en) | 2021-08-31 | 2021-08-31 | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113797215B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114748132A (en) * | 2022-03-01 | 2022-07-15 | 四川大学华西医院 | Clinical special episome remove device of orthopedics |
| CN118059085A (en) * | 2024-01-19 | 2024-05-24 | 黄山学院 | Composition containing eucommia ulmoides alcohol and quercetin as well as preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105859804A (en) * | 2016-04-27 | 2016-08-17 | 江西普正制药有限公司 | Eucommia ulmoides extract as well as preparation method and application thereof |
-
2021
- 2021-08-31 CN CN202111013751.3A patent/CN113797215B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105859804A (en) * | 2016-04-27 | 2016-08-17 | 江西普正制药有限公司 | Eucommia ulmoides extract as well as preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| "基于信号通路的中药有效成分治疗骨质疏松机制研究";赵金龙等;《中草药》;20201231;第51卷(第23期);第6084-6094页，尤其是第6086页左栏第1段 * |
| "基于网络药理学和分子对接研究牛膝_杜仲药对治疗膝骨性关节炎的作用机制";张涛;《中成药》;20210811;第44卷(第7期);第2369-2374页，尤其是第2373页左栏讨论部分 * |
| "柳蒿化学成分研究";王金兰等;《中草药》;20160731;第47卷(第13期);第2241-2245页，尤其是第2245页左栏最后1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113797215A (en) | 2021-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113797215B (en) | Composition containing pinoresinol and cycloolivil 9-glycoside and preparation method and application thereof | |
| CN103751310A (en) | External traditional Chinese medicinal preparation for treating fasciitis and preparation method thereof | |
| CN104013929B (en) | Rheumatism pain relief medicine for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof | |
| WO2021062888A1 (en) | Complex composition with function of promoting bone and joint health and application thereof | |
| GB2581592A (en) | Preparation procedure for panax notoginseng medicinal liquor for oral administration for treating rheumatic ostalgia | |
| CN104056076A (en) | Bone-strengthening medicinal liquor | |
| CN114470121B (en) | Medicine for treating osteoarthritis and preparation method thereof | |
| CN105456644A (en) | External lotion for perineal laceration postoperative nursing and preparation method thereof | |
| CN112656924A (en) | A Chinese medicinal composition with antiinflammatory, analgesic, and antibacterial effects, and its preparation method | |
| CN111643540A (en) | Eucommia ulmoides extract for treating lumbar muscle strain and preparation method thereof | |
| CN107213250B (en) | Traditional Chinese medicine composition for preventing and treating rheumatoid arthritis and preparation method thereof | |
| CN105343277A (en) | Skin-nursing traditional Chinese medicine ointment for treating tinea versicolor and preparation method of skin-nursing traditional Chinese medicine ointment | |
| Afreen et al. | Therapeutic uses of earthworm–a review | |
| CN105311210A (en) | Pharmaceutical composition for treating rheumatoid bone diseases | |
| CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof | |
| CN116763834B (en) | Traditional Chinese medicine composition and preparation for treating arthralgia as well as preparation method and application of traditional Chinese medicine composition and preparation | |
| CN116549522B (en) | Application of traditional Chinese medicine composition in gout | |
| CN107485665A (en) | Chinese medicine composition and its related preparations for anti-premature ovarian failure | |
| CN116603045A (en) | External plaster for relieving rheumatic leg pain and preparation method thereof | |
| CN105412395A (en) | Traditional Chinese medicine composition for treating hyperostosis and preparation method thereof | |
| CN118649208A (en) | Pharmaceutical composition for treating gout and preparation method and application thereof | |
| CN116983348A (en) | Traditional Chinese medicine composition for inhibiting bone cancer pain and preparation and application thereof | |
| CN1073433C (en) | Medicine for psoriasis and preparing method thereof | |
| CN116098947A (en) | Preparation process of compound sea snake combined preparation | |
| CN116983357A (en) | Tibetan medicine composition for treating influenza and viral hepatitis as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |